info@marketfacts.ca +1-807 788 8478
Anavex is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative and neurodevelopmental disorders, using its proprietary SIGMACEPTOR™ platform to target sigma-1 receptor pathways.
Anavex Life Sciences Corp. (NASDAQ: AVXL) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for central nervous system (CNS) disorders, with a primary focus on Alzheimer’s disease, Parkinson’s disease, and Rett syndrome. The company’s proprietary SIGMACEPTOR™ platform leverages sigma-1 receptor (S1R) agonists to restore cellular homeostasis, targeting key mechanisms such as oxidative stress, inflammation, and mitochondrial dysfunction.
Arbutus Biopharma Corporation (NASDAQ: ABUS) is a clinical-stage biopharmaceutical company headquartered in Warminster, Pennsylvania, focused on developing innovative therapies to treat chronic hepatitis B virus (HBV) infection. The company aims to achieve a functional cure for HBV by targeting multiple stages of the virus lifecycle through a combination of RNA interference (RNAi) therapies, capsid inhibitors, immune modulators, and HBV RNA destabilizers. Its lead product candidates include AB-729, an RNAi therapeutic designed to reduce hepatitis B surface antigen (HBsAg), and AB-836, a capsid inhibitor. Leveraging proprietary lipid nanoparticle (LNP) technology for RNA-based therapies, Arbutus is also engaged in collaborations to advance its pipeline. Arbutus is strategically positioned in the biopharmaceutical landscape, aiming to address unmet medical needs in HBV treatment. By pursuing a comprehensive approach that integrates cutting-edge science and collaboration, Arbutus continues to advance its pipeline and work toward transformative solutions for HBV patients globally.
Sutro Biopharma, Inc. (NASDAQ: STRO), headquartered in South San Francisco, CA, is a pioneering biopharmaceutical company founded on April 21, 2003, by James R. Swartz and Sutanto Widjaja. Their core mission revolves around revolutionizing cancer and autoimmune therapeutics through innovative drug discovery, development, and manufacturing.
Veru Inc. is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast cancer and prostate cancer.